Form 4 for MAZE Maze Therapeutics, Inc.
Accepted 2025-12-31 00:00:00 ET · period of report 2025-12-29 · accession 0002050422-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-31 | 2025-12-29+ | MAZE | Bachrodt Amy | SVP, Fin | M - OptEx | $10.42 | +15.0K | 13.1K | New | +$156.3K |
| DM | 2025-12-31 | 2025-12-29+ | MAZE | Bachrodt Amy | SVP, Fin | S - Sale+OE | $40.41 | -15.0K | 13.6K | -53% | -$606.2K |
| DM | 2025-12-31 | 2025-12-29+ | MAZE | Bachrodt Amy | SVP, Fin | M - OptEx | $0.00 | -15.0K | 2,581 | -85% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-30 | M | A | 2,395 | $10.42 | 15,360 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-30 | S | D | 5,000 | $40.08 | 12,965 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.36 per share, inclusive. |
| 3 | Common | Common Stock | 2025-12-30 | M | A | 2,605 | $10.42 | 17,965 | D | — | — | |
| 4 | Common | Common Stock | 2025-12-29 | S | D | 600 | $41.16 | 12,965 | D | — | — | (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.04 to $41.29 per share, inclusive. |
| 5 | Common | Common Stock | 2025-12-29 | S | D | 9,400 | $40.54 | 13,565 | D | — | — | (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.04 to $40.94 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4. |
| 6 | Common | Common Stock | 2025-12-29 | M | A | 9,876 | $10.42 | 22,965 | D | — | — | |
| 7 | Common | Common Stock | 2025-12-29 | M | A | 124 | $10.42 | 13,089 | D | — | — | |
| 8 | Derivative | Stock Option (Right to Buy) | 2025-12-29 | M | D | 9,876 | $0.00 | 23,834 | D | $10.42 · — to 2034-04-23 | 9,876 Common Stock | (F6) The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| 9 | Derivative | Stock Option (Right to Buy) | 2025-12-29 | M | D | 124 | $0.00 | 2,396 | D | $10.42 · — to 2031-02-01 | 124 Common Stock | (F5) The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2025. |
| 10 | Derivative | Stock Option (Right to Buy) | 2025-12-30 | M | D | 2,395 | $0.00 | 1 | D | $10.42 · — to 2031-02-01 | 2,395 Common Stock | (F5) The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2025. |
| 11 | Derivative | Stock Option (Right to Buy) | 2025-12-30 | M | D | 2,605 | $0.00 | 2,581 | D | $10.42 · — to 2032-10-26 | 2,605 Common Stock | (F7) The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on November 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |